EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE

Neil P Shah iD, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, Sarah M Larson, Susanne Saussele, Delphine Rea iD, François-Xavier Mahon, Moshe Yair Levy, María Teresa Gómez-Casares, Michael J Mauro, Oumar Sy, Patricia Martin-Regueira und 1 weitere

British Journal of Haematology · 2023-09 · 202 (5) · 942-952

DOI: 10.1111/bjh.18883 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 29.05.2023. Verfasst von Neil P Shah und 12 weiteren Autor:innen. Beteiligte Einrichtung: UCSF School of Medicine, San Francisco, California, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with chronic myeloid leukaemia in chronic phase (CML‐CP) who have a sustained deep molecular response (DMR) are eligible to discontinue treatment and attempt treatment‐free remission (TFR). In the DASFREE study ( ClinicalTrials.gov ; NCT01850004), the 2‐year TFR rate after dasatinib discontinuation was 46%; here we present the 5‐year update. Patients with a stable DMR after ≥2 years of dasatinib therapy discontinued treatment and were followed for 5 years. At a minimum follow‐up of 60 months, in 84 patients discontinuing dasatinib, the 5‐year TFR rate was 44% ( n = 37). No relapses occurred after month 39 and all evaluable patients who relapsed and restarted dasatinib ( n = 46) regained a major molecular response in a median of 1.9 months. The most common adverse event during the off‐treatment period was arthralgia (18%, 15/84); a total of 15 withdrawal events were reported in nine patients (11%). At the 5‐year final follow‐up, almost half of the patients who discontinued dasatinib after a sustained DMR maintained TFR. All evaluable patients who experienced a relapse quickly regained a DMR after restarting dasatinib, demonstrating that dasatinib discontinuation is a viable and potentially long‐term option in patients with CML‐CP. The safety profile is consistent with the previous report.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansDasatinibTreatment OutcomeNeoplasm Recurrence, Local

Stichwörter der Autor:innen

chronic phase chronic myeloid leukaemiadasatinibdeep molecular responsemajor molecular responsetreatment-free remission

Substanzen

DasatinibProtein Kinase Inhibitors

Autor:innen und Institutionen

  • UCSF School of Medicine, San Francisco, California, USA.
  • Servicio Hematología y Hemoterapia, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
  • Servicio de Hematología y Hemoterapia, Hospital Regional Universitario de Málaga, IBIMA, Málaga, Spain.
  • David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany.
  • Adult Hematology Department, Hôpital Saint-Louis, Paris, France.

ORCID-Profile: Neil P Shah, Delphine Rea

Förderung

  • NCI NIH HHS

Zitieren

APA

Shah, N. P., García-Gutiérrez, V., Jiménez-Velasco, A., Larson, S. M., Saussele, S., Rea, D., Mahon, F. X., Levy, M. Y., Gómez-Casares, M. T., Mauro, M. J., Sy, O., Martin-Regueira, P., & Lipton, J. H. (2023). Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE. British Journal of Haematology, 202(5), 942-952. https://doi.org/10.1111/bjh.18883

Vancouver

Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, et al. Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE. British Journal of Haematology. 2023;202(5):942-952. doi:10.1111/bjh.18883

BibTeX
@article{Shah2023,
  author = {Shah, Neil P and García-Gutiérrez, Valentín and Jiménez-Velasco, Antonio and Larson, Sarah M and Saussele, Susanne and Rea, Delphine and Mahon, François-Xavier and Levy, Moshe Yair and Gómez-Casares, María Teresa and Mauro, Michael J and Sy, Oumar and Martin-Regueira, Patricia and Lipton, Jeffrey H},
  title = {Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE},
  journal = {British Journal of Haematology},
  year = {2023},
  volume = {202},
  number = {5},
  pages = {942--952},
  doi = {10.1111/bjh.18883}
}
Kostenlos starten →